Related Experiment Videos
Stage IIIC endometrioid corpus cancer includes distinct subgroups
Andrea Mariani1, Maurice J Webb, Gary L Keeney
1Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Gynecologic Oncology
|December 7, 2002
Summary
Stage IIIC endometrioid corpus cancer presents two distinct patient groups based on extrauterine disease spread. Nodal-only involvement (stage IIIC(0)) shows significantly better survival than nodal plus other site involvement (stage IIIC(ab)).
Area of Science:
- Gynecologic Oncology
- Surgical Pathology
- Cancer Staging
Background:
- Stage IIIC corpus cancer is a heterogeneous substage with variable patient outcomes.
- The extent of extrauterine disease significantly impacts prognosis in advanced endometrial cancer.
Purpose of the Study:
- To assess outcomes of stage IIIC corpus cancer patients based on the extent of extrauterine disease.
- To identify distinct prognostic subgroups within stage IIIC endometrioid endometrial cancer.
Main Methods:
- Retrospective analysis of 46 patients with surgical stage IIIC endometrioid corpus cancer treated between 1984-1993.
- Patients were categorized into stage IIIC(0) (lymph node involvement only) and stage IIIC(ab) (nodal plus other sites of spread).
- Survival rates (CSS, RFS) and sites of relapse were analyzed.
Main Results:
- Stage IIIC(0) patients had a 5-year cause-specific survival (CSS) of 72% and recurrence-free survival (RFS) of 68%.
- Stage IIIC(ab) patients had a significantly lower 5-year CSS of 33% and RFS of 25% (P < 0.01).
- Recurrence patterns differed, with a higher rate of extranodal failure in stage IIIC(ab) disease.
Conclusions:
- FIGO surgical stage IIIC endometrioid corpus cancer comprises two distinct subgroups: nodal-only (IIIC(0)) and nodal plus other site involvement (IIIC(ab)).
- These subgroups exhibit significantly different survival rates and relapse patterns.
- Tailored treatment strategies may be necessary for each subgroup.